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Abstract
Now that numerous high-quality complete genome sequences are available, many efforts are focusing
on the “second genomic code”, namely the code that determines how the precise temporal and spatial
expression of each gene in the genome is achieved. In this regard, the elucidation of transcription
regulatory networks that describe combined transcriptional circuits for an organism of interest has
become valuable to our understanding of gene expression at a systems level. Such networks describe
physical and regulatory interactions between transcription factors (TFs) and the target genes they
regulate under different developmental, physiological, or pathological conditions. The mapping of
high-quality transcription regulatory networks depends not only on the accuracy of the experimental
or computational method chosen, but also relies on the quality of TF predictions. Moreover, the total
repertoire of TFs is not only determined by the protein-coding capacity of the genome, but also by
different protein properties, including dimerization, co-factor interactions and post-translational
modifications. Here, we discuss the factors that influence TF functionality and, hence, the
functionality of the networks in which they operate.
1 Introduction
Transcription regulatory networks can be represented as graph models that combine physical
and regulatory interactions between TFs and their target genes (reviewed in ref. 1). Several
methods that can be used to identify physical interactions between TFs and their targets have
been developed and applied to the study of both yeast and metazoan transcription regulatory
networks. These include TF-centered methods such as chromatin immunoprecipitations,2–4
protein binding microarrays,5 DamID6,7 and bacterial one-hybrid assays,8 as well as gene-
centered methods such as high-throughput yeast one-hybrid assays.9 The TF-DNA interaction
data obtained by these methods are often visualized into network models. Fig. 1 depicts a
hypothetical network that contains several of the architectural and topological network features
described to date, including TF hubs (TFs that bind a large number of target genes), target gene
hubs (genes bound by a large number of TFs), and TF modules (sets of TFs that share numerous
target genes). Metazoan TF hubs were uniquely revealed in the nematode Caenorhabditis
elegans by using gene-centered yeast one-hybrid assays.10,11 Specifically, we found that,
whereas the majority of TFs bind only few promoters, a small subset of TFs bind up to 40%
of all promoters tested. This suggests that these proteins play a more essential role in regulating
transcription than most other TFs. By performing chromatin immunoprecipitation with eight
TFs in the budding yeast Saccharomyces cerevisiae, Snyder and colleagues12 showed that the
genes that code for two of these TFs, MGA1 and PHD1, were themselves targeted by all eight
TFs, suggesting that these two TFs may be target gene hubs. Interestingly, MGA1 and PHD1
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are master regulators of pseudohyphal growth. The authors suggest that genes regulated by
large number of TFs may function as master regulators of biological processes. In agreement
with this, we found that the promoter of the master regulator of D-type GABA-ergic motor
neurons unc-30 in C. elegans can interact with 36 different TFs.11
TF modules are another feature of transcription regulatory networks that have recently
emerged.11 TF modules are distinct from more extensively studied general network modules
that are defined as highly interconnected groups of nodes without regard for directionality or
node type (i.e., TFs vs. target genes).13,14 We have defined TF modules as sets of TFs that
share many of their target genes (Fig. 1).11 As such, these are uniquely found in bipartite
transcription regulatory networks. Both general network modules and TF modules may reflect
functionality, for instance within a cell or tissue type, or regarding a particular biological
process. Finally, transcription regulatory networks are composed of recurring circuits, referred
to as network motifs. For instance, feed forward loops are found frequently in networks from
both pro- and eukaryotic organisms. Such motifs represent widely used regulatory mechanisms
that can, for instance, be used to stabilize gene expression.15,16
The transcription regulatory networks that have been described to date represent compilations
of multiple events that take place during the lifetime of an organism collapsed into a single
model. However, in reality, only a subset of the network is active in particular cell types, under
different developmental or physiological conditions, or at any given time.17–19 In addition,
each TF in regulatory networks is represented as a single node, whereas it is known that TFs
exist in many different functional forms that are determined by a variety of factors including
post-translational modifications and dimerization. These factors themselves may depend on
specific developmental or physiological conditions. Each TF form may interact with distinct
target genes, or with the same target gene, but under different conditions. Here, we discuss the
factors that need to be taken into account to determine how many functional TFs occur in an
organism of interest, and how this information can be incorporated into transcription regulatory
network models to study differential gene expression at a systems level.
2 Transcription factor predictions
There are two classes of TFs: basal TFs that are involved in transcription of most, if not all,
genes, and regulatory TFs that control only subsets of genes.20 For the understanding of
differential gene expression at a systems level, we only consider regulatory TFs (hereafter
referred to as TFs). TFs interact with their target genes by binding specific cis-regulatory gene
elements through a sequence-specific DNA binding domain. Different DNA binding domains
are used to group TFs into TF families. Examples of DNA binding domains include basic
region helix–loop–helix domains (bHLH), homeodomains and various types of zinc fingers.
Computational tools have been developed both to define consensus DNA binding domains and
to predict additional TFs of that family encoded by a genome of interest.21,22 We found that,
although such computational tools are powerful, they do incorporate false predictions and miss
many known TFs.23 For instance, by using a combination of computational tools and extensive
manual curation we predicted a high-quality compendium of 934 TFs in the nematode
Caenorhabditis elegans, which extended purely computational predictions by ∼50%.23
However, even though this compendium is more complete than previous collections, it is not
yet comprehensive as algorithms and experimental assays continue to improve and, therefore,
additional TFs continue to be discovered.24
3 DNA binding domains
Over the past decades, many different sequence-specific DNA binding domains have been
uncovered. However, we propose that it is unlikely that all DNA binding domains are known.
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This is because, by applying yeast one-hybrid assays to only 112 C. elegans gene promoters,
we have already discovered 11 C. elegans proteins that robustly interact with their target
promoters in yeast, but that do not possess a known DNA binding domain. By using chromatin
immunoprecipitation assays in yeast, we confirmed that these interactions are direct for nine
of these proteins.10,11 We do not know yet whether these proteins directly bind to DNA or if
they are recruited to their target promoters by interacting with other DNA binding proteins.
Future structure–function analysis will provide insight into the mechanism of action of these
novel putative TFs. Importantly, the cataloging of the DNA binding domain(s) of these proteins
may enable the identification of additional proteins with similar domains in C. elegans, and
perhaps in other organisms as well.
4 Alternative splicing
In metazoans, many gene transcripts, including those encoding TFs, are alternatively spliced,
which often leads to multiple variants of a protein. Interestingly, it has been found that TF-
encoding genes in mice undergo alternative splicing more frequently than other genes.25
Alternative splicing may lead to TFs with different functions. For instance, DNA binding
domains or transcription regulatory domains may be included or excluded from the TF variant.
At least 144 C. elegans TFs undergo alternative splicing, resulting in 379 different proteins,
30 of which lack a DNA-binding domain.23 The latter may function as regulators of TF
function, for instance by titrating interaction partners of the corresponding TFs that do possess
a DNA binding domain. Several C. elegans TFs contain more than one DNA binding domain
and alternative splicing can affect which domains are present in the different protein products.
For instance, several DAF-16 variants are generated as a result of alternative splicing, and each
variant carries a unique combination of domains26 (Fig. 2(A)). DAF-16 is a critical regulator
of various physiological processes including fat storage, aging, and the formation of dauers
(an alternative larval stage of development, resistant to many forms of stress). It contains two
potential forkhead DNA binding domains and is known to bind or regulate numerous target
genes.27 It is tempting to speculate that each forkhead domain is responsible for the interaction
with a distinct set of target genes, each of which may be involved in a particular biological
process. A human example involves the homeodomain proteins hepatocyte nuclear factor
HNF1 and vHNF1. There are three HNF1 splice variants, each of which encodes a protein with
varying transcription activation properties. vHNF1 is also differentially spliced and one of the
resulting protein products, vHNF1-C, functions as a trans-dominant repressor of all three
HNF1 variants.28 TF variants may be expressed in different cell types or under particular
conditions, leading to variable outputs of the transcriptional circuits in which they function.
For instance, the HNF isoforms are differentially expressed in the human digestive tract, liver
and kidney, where they may either regulate distinct target genes or, alternatively, the same
target genes but at different levels. Genome-scale analyses of alternative splicing, for instance
using whole genome or exon junction tiling arrays,29 will greatly facilitate the accurate
identification of all TF variants that are produced in each cell and tissue type, and in various
model organisms.
5 Dimerization
Several TFs bind DNA as obligatory dimers, including members from the basic region leucine
zipper (bZIP), bHLH and nuclear hormone receptor (NHR) families.30–32 Dimerization
should be taken into account when considering the total complement of functional TFs because,
if a particular TF only functions when it dimerizes with another TF, the dimer should be
considered a single functional unit. Dimerization can affect the total number of functional TFs
in different ways (Fig. 2(B)). In one model, each TF from a family can dimerize with itself and
any other member of that family. If this would be the case, the number of functional TFs would
be dramatically greater than the number of individually predicted TFs. For instance,
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dimerization between all 274 C. elegans NHRs23 would result in a total of 37675 NHR dimers.
In another model, each TF dimerizes exclusively with one other TF of the same family. If this
were the case for the C. elegans NHRs, this would result in 137 functional TF complexes,
which would reduce the total number of functional TFs. In a third, intermediate model, one or
more TFs from a family could serve as central dimerization partners that can interact with
multiple members of the relevant TF family. Although no comprehensive data regarding TF
dimerization is as yet available, our preliminary data indicate that this third model is likely
most relevant (C. A. G. and A. J. M. W., in preparation). Systematic protein–protein interaction
mapping efforts will be required to identify all functional TF dimers. High-throughput yeast
two-hybrid assays33 are particularly well suited for this task as they identify binary
interactions. For instance, we found by high-throughput yeast two-hybrid assays that NHR-49
serves as a dimerization hub, that can interact with at least 15 other NHRs.24 In the future, it
will be important not only to identify all TF dimers, but to also determine the DNA-binding
specificities of each dimer and where and when dimerization partners are co-expressed.
6 Post-translational modifications
Many proteins, including TFs, are post-translationally modified under different conditions and
by different modifiers. Several post-translational modifications of TFs have been reported,
including phosphorylation, hydroxylation, acetylation, ubiquitination and sumoylation (Fig. 2
(C)).34 Such modifications often result from the activation of signal transduction pathways in
response to environmental stimuli or developmental cues. Post-translational modifications can
affect the regulatory activity of a TF, as well as its localization or stability. For instance,
estrogen receptor β (ERβ), normally activated by ligand, can be phosphorylated by MAP kinase
(MAPK) which leads to recruitment of the steroid receptor coactivator-1 (SRC-1) and ligand-
independent activation of target genes.35 ERα can be acetylated by p300 at conserved lysine
residues resulting in enhanced DNA-binding activity and, perhaps, ligand-dependent
transcriptional activation.36 For most TFs it is not clear which modified forms exist and how
these forms function to regulate gene expression. For a thorough understanding of gene
regulatory networks, it will be important to determine which modification each TF is subjected
to, under which circumstances, and how these modifications affect TF functionality.
7 Ligands
Many TFs become activated or inactivated as a result of ligand binding (Fig. 2(D)). One of the
most prominent classes of ligand-dependent TFs is the NHR family, which includes ER,
androgen receptor (AR), peroxisome proliferator-activated receptors (PPARs), retinoic acid
receptor (RAR) and others. NHR ligands are hydrophobic molecules that can freely diffuse
into the nucleus where they specifically interact with their target receptors. Most NHRs become
potent transcriptional activators upon ligand binding. Human ER has been studied extensively
because of its association with the development of breast cancer.37 A number of ER ligands
(endogenous and exogenous) have been identified, some of which are non-steroidal compounds
that are referred to as selective ER modulators (SERMs). Whereas steroidal compounds such
as estrogen function to naturally modulate ER activity, SERMs such as tamoxifen are used in
cancer treatment. Different ligands bind to ER with varying affinities and have different effects.
Depending on tissue and cell-type context, ligands induce conformational changes in ER that
promote transcriptional activation, whereas others promote transcriptional repression.38 The
ligand(s) for most NHRs remain to be identified, and, therefore, such NHRs are referred to as
“orphan” receptors. For instance, the nematode C. elegans has 274 predicted NHRs,23 but a
ligand (dafachronic acid) has only been identified for a single NHR, DAF-12.39
Another class of ligand-binding TFs is the bHLH-PAS sub-family that includes the aryl
hydrocarbon receptor (AHR). AHR can interact with a variety of exogenous compounds or
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toxins such as dioxin, and mediate a biological response (for a review see ref. 40). The range
of compounds that can activate AHR is still under investigation, and although most appear to
be exogenous in origin, it has been proposed that endogenous AHR ligands may play a role in
organism development or homeostasis.41 Indeed, the C. elegans ortholog of AHR, ahr-1, is
required for the proper development and specification of touch-receptor neurons, interneurons,
and motor neurons.42,43
8 Co-factors
Regulatory TFs often activate or repress transcription, either by recruiting the RNA polymerase
II machinery, or by preventing its access to the transcription start site. While many TFs interact
directly with general TFs or components of RNA polymerase II, others function by interacting
with intermediate proteins called co-factors (Fig. 2(E)).44–46 Depending on environmental or
developmental circumstances, the same TF can interact with different coactivators or
corepressors, illustrating the versatility of TFs in carrying out opposing regulatory effects in
different contexts. RAR, for instance, can recruit the NCoR/SMRT corepressor complexes
thereby repressing transcriptional activity of its target genes. Upon binding its ligand retinoic
acid, however, RAR changes conformation and adopts a form capable of recruiting coactivator
complexes and subsequently activates transcription.45 Interestingly, cofactor interactions can
also affect DNA binding specificity,47 implying that different TF-cofactor pairs may interact
with different sets of target genes. Future large-scale genomic and proteomic experiments are
needed to identify the full spectrum of ligands and co-factors each TF in an organism can
interact with and to unravel how these interactions affect the biochemical and biological
function of each TF.
9 Transcription factor variants and disease
TFs play a crucial role in numerous diseases, including congenital disorders and cancer.
Mutations in TF-encoding genes can result in loss-of-function, gain-of-function or neomorph
TFs that attain a function not shared by the original TF. One of the best-studied TFs mutated
in cancer is p53, a tumor suppressor gene that is inactivated by mutation in most human cancers.
Interestingly, it appears that some mutations can also convert p53 into an oncogene.48 p53
regulates the expression of various cell cycle inhibitors and proteins involved in apoptosis. It
will be interesting to see how the different forms of mutant p53 are affected in their biochemical
and biological functions.
Several mutated TFs have been found to result in a variety of human congenital disorders. For
instance, altered dimerization between the bHLH TFs Twist1 and Hand2 was found in patients
with Saethre–Chotzen syndrome.49 Common neomorph TF variants that are found in instances
of leukemia are fusion proteins resulting from chromosomal translocation/inversion (Fig. 2
(F)). For example, an inversion on murine chromosome 16 leads to an aberrant Cbfb-MYH11
fusion protein, resulting in the development of acute myeloid leukemia.50 It will be important
to understand the variety of mutant forms of TFs that exist in different diseases and how they
perturb the regulatory networks that contribute to a disease state.
10 Conclusions
Although complete genome sequences have provided a great first step toward the
comprehensive identification of the compendium of TFs that function in an organism of
interest, we are far from having a complete picture of all the protein variants that may exist for
each predicted TF. As we discussed here, there are numerous factors that affect the functional
states of TFs throughout development, homeostasis, and in disease. Since the gene count is
strikingly similar between organisms of widely different complexity, a larger number of TF
permutations may contribute to more intricate regulatory networks in higher eukaryotes such
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as humans. In the future, different TF forms need to be incorporated as individual nodes in
transcription regulatory networks to facilitate network modeling and hypothesis derivation
(Fig. 3).
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Fig. 1.
The mapping of physical interactions between transcription factors (TFs) and their target genes
has resulted in the discovery of several interesting network features, some of which are shown
here. Some TFs (circles) target a disproportionately large number of genes (diamonds) and are
referred to as TF hubs. Sets of TFs that share many target genes are referred to as TF modules.
Target gene hubs interact with a disproportionately large number of TFs.
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Fig. 2.
Various factors influence the functionality of TFs and impact transcription regulatory network
modeling and analysis. Whether a TF binds to a promoter, and activates or represses
transcription, depends on: (A) alternative splicing that may produce TF variants that carry
unique combinations of functional domains involved in the regulation of gene expression. The
example shows the C. elegans daf-16 gene that produces many splice variants, resulting in TFs
that contain either of two possible forkhead DNA-binding domains, or neither. (B) Dimerizing
TFs potentially combine in different ways to generate a large array of different hetero- or
homodimers, each with its own function. (C, D) Some TFs may have an altered function after
ligand binding or post-translational modifications (PTMs), such as phosphorylation (Phos),
hydroxylation (OH), acetylation (Ac), ubiquitination (Ub), or sumoylation (Sumo). Such
modifications can induce different conformational changes, thereby affecting TF functionality.
(E) Co-factors can mediate varying affects of TF activity. (F) Mutation or translocation of TF-
encoding genes can result in TFs with reduced, enhanced, or novel activity. The asterisk
indicates a point mutation and the horizontal line depicts the breaking point of translocation
within the chromosome that carries the TF-encoding gene.
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Fig. 3.
Whereas traditional transcription regulatory networks have been visualized using a single node
for a TF protein, the use of individual nodes for each functional TF state may help to depict
the regulatory capacity of each TF. TF (blue circle) variant “a” forms heterodimers, variant
“b” is post-translationally modified and variant “c” is a result of a mutation in the gene encoding
the TF. Each variant has different target genes (diamonds) and/or different effects on those
targets (arrows = transcriptional activation, flat arrows = repression).
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